MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00520-020-05972-2

Медицинская библиотека · Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021

Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study.

Raimondi Alessandra, Corallo Salvatore, Lonardi Sara, Antoniotti Carlotta, Rimassa Lorenza, Amatu Alessio, Tampellini Marco, Racca Patrizia, Murialdo Roberto, Clavarezza Matteo, Zaniboni Alberto, Toscano Giuseppe, Tomasello Gianluca, Petrelli Fausto, Antonuzzo Lorenzo, Giordano Monica, Cinieri Saverio, Longarini Raffaella, Niger Monica, Antista Maria, Ambrosini Margherita, Pagani Filippo, Prisciandaro Michele, Randon Giovanni, de Braud Filippo, Di Bartolomeo Maria, Pietrantonio Filippo, Morano Federica

СтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

INTRODUCTION

The combination of anti-EGFRs and doublet chemotherapy is considered the optimal upfront option for patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC). The prophylactic or reactive treatment with tetracyclines for EGFR inhibitor-induced skin toxicity is currently clinical practice, though non-conclusive results are available.

METHODS

We performed a post hoc analysis of the Valentino study that randomized RAS wild-type mCRC patients to two panitumumab-based maintenance regimens after the first-line induction, aimed at assessing the safety and efficacy of the administration of a pre-emptive doxycycline prophylaxis for anti-EGFR-related skin toxicity. We assessed the rate of treatment-related and panitumumab-related adverse events (AEs), treatment intensity, progression-free survival (PFS), and overall survival (OS).

RESULTS

A total of 226 patients, out of the 229 enrolled in the Valentino study, were eligible for the analysis. Overall, 143 (63%) and 83 (37%) patients received or not the antibiotic prophylaxis for skin toxicity. Any grade and G3/4 panitumumab-related AEs were reported in 89% versus 92% (p = 0.650) and 27% versus 27% (p = 1.000) patients who received or not the pre-emptive prophylaxis, respectively. Any grade and G3/4 skin rash occurred in 81% versus 90% (p = 0.085) and 27% versus 25% (p = 0.876) patients receiving or not the prophylaxis, respectively. No significant differences in terms of treatment duration, treatment delays or dose reductions, PFS, and OS were observed in the two sub-populations.

CONCLUSION

The adequate management of anti-EGFR-related skin toxicity is fundamental to optimize the outcome of mCRC patients, balancing the survival benefit with patients' quality of life, especially in the first-line setting.

Для цитирования: Raimondi Alessandra, Corallo Salvatore, Lonardi Sara, Antoniotti Carlotta, Rimassa Lorenza, Amatu Alessio, Tampellini Marco, Racca Patrizia, Murialdo Roberto, Clavarezza Matteo, Zaniboni Alberto, Toscano Giuseppe, Tomasello Gianluca, Petrelli Fausto, Antonuzzo Lorenzo, Giordano Monica, Cinieri Saverio, Longarini Raffaella, Niger Monica, Antista Maria, Ambrosini Margherita, Pagani Filippo, Prisciandaro Michele, Randon Giovanni, de Braud Filippo, Di Bartolomeo Maria, Pietrantonio Filippo, Morano Federica. Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2021. DOI: 10.1007/s00520-020-05972-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.